ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Administrative Data"

  • Abstract Number: 0566 • ACR Convergence 2020

    Healthcare Utilization and Costs Prior to Diagnosis of ANCA Vasculitis in Medicare Beneficiaries

    Shirley Huang1, Xintong Li2, Joehl Nguyen2, Jacob Robinson2, Susan Hogan3, Vimal Derebail3 and Carolyn Thorpe2, 1University of North Carolina at Chapel Hill, Chapel Hill, 2University of North Carolina Eshelman School of Pharmacy, Chapel Hill, 3University of North Carolina Kidney Center, Chapel Hill

    Background/Purpose: Antineutrophil cytoplasmic antibody (ANCA) vasculitis (AV) is a complex group of autoimmune disorders affecting blood vessels in multiple organ systems. Delays in diagnosis are…
  • Abstract Number: 1031 • ACR Convergence 2020

    Real World Treatment Patterns Among Patients with Psoriatic Arthritis Treated with Ixekizumab

    Mwangi Murage1, Nicole Princic2, Julie Park2, William Malatestinic1, Baojin Zhu1, Bilal Atiya1, Scott Kern1, Keri Stenger1, Aubrey Sprabery1 and Alexis Ogdie3, 1Eli Lilly and Company, Indianapolis, IN, 2IBM Watson Health, Cambridge, MA, 3University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Psoriatic arthritis (PsA) is a systemic condition estimated to affect 0.05%-0.25% of the United States (US)1 population. With approval of ixekizumab (a selectively binding…
  • Abstract Number: 0580 • ACR Convergence 2020

    Risk of Severe Acute Localized Reactions for Different Intra-Articular Hyaluronic Acid Knee Injections in a Real World Setting

    Kevin Ong1, Jack Farr2, Louis McIntyre3, Andrew Gudeman2, Iain Murray4, Charles Hummer5, Wilson Ngai6, Heather Good7, Edmund Lau8 and Roy Altman9, 1Exponent, Philadelphia, 2Indiana University Department of Orthopaedic Surgery, Indianapolis, 3US Orthopedics, Tarrytown, 4Department of Orthopaedics, The University of Edinburgh, Edinburgh, United Kingdom, 5Premier Orthopaedics and Sports Medicine, Glen Mills, 6Sanofi US, Bridgewater, 7Sanofi US, Bridgewater, FL, 8Exponent, Menlo Park, 9David Geffen School of Medicine, University of California, Agua Dulce, CA

    Background/Purpose: Case reports of severe acute localized reactions (SALR) following intra-articular (IA) hyaluronic acid (HA) injections for knee osteoarthritis (OA) have been described. These have…
  • Abstract Number: 1281 • ACR Convergence 2020

    Opioid-Related Encounters as a Predictor of 30-Day Readmissions in Lupus

    Christie Bartels1, Maria Schletzbaum2, Yi Chen3 and Amy Kind4, 1University of Wisconsin School of Medicine and Public Health, Department of Medicine, Division of Rheumatology, Madison, WI, 2University of Wisconsin-Madison School of Medicine and Public Health, Department of Population Health Sciences, Madison, WI, 3University of Wisconsin School of Medicine and Public Health, Department of Biostatistics and Medical Informatics, Madison, WI, 4University of Wisconsin-Madison School of Medicine and Public Health, Department of Medicine, Health Services and Care Research Program, Geriatrics Division, Madison, WI

    Background/Purpose: One in four Medicare hospitalizations with systemic lupus erythematosus (SLE) results in readmission within 30 days, with “injuries and poisonings” as the second most…
  • Abstract Number: 0678 • ACR Convergence 2020

    Patient Characteristics and Patterns of Urate-lowering Treatments in Older Patients with Incident Gout

    Kazuki Yoshida1, Jun Liu2, Daniel H Solomon3 and Seoyoung Kim3, 1Brigham & Women's Hospital and Harvard Medical School, Boston, MA, 2Brigham and Women's Hospital, Boston, 3Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Gout is a common inflammatory arthritis caused by monosodium urate crystal deposition in the joints.  Despite this well-understood pathophysiologic mechanism of disease and ACR and EULAR…
  • Abstract Number: 1423 • ACR Convergence 2020

    Declining In-Hospital Mortality in Vasculitis: A 17-year U.S. National Study

    Jasvinder Singh1 and John Cleveland1, 1University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: To our knowledge, only a few population-based studies for vasculitis mortality exist; and most are limited to vasculitis sub-types. Therefore, our study objective was…
  • Abstract Number: 0689 • ACR Convergence 2020

    The Changing Epidemiology of Inpatient Gout and Associated Mortality: A 17-year National Study

    Jasvinder Singh1 and John Cleveland1, 1University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Knowledge gaps exist regarding time-trends for the main causes (Cardiac/renal disease vs. infections) hospitalizations in gout. Therefore, we examined whether specific causes (cardiovascular, renal,…
  • Abstract Number: 1475 • ACR Convergence 2020

    Predictors of Thirty-Day Hospital Readmissions in Systemic Lupus Erythematosus in the US: A Nationwide Study

    Rayan Najjar1, Swetha Ann Alexander2, Grant Hughes1, Jinoos Yazdany3 and Namrata Singh4, 1University of Washington, Seattle, WA, 2University of Connecticut, Hartford, CT, 3UCSF, San Francisco, CA, 4University of Washington, Bellevue, WA

    Background/Purpose: For individuals with systemic lupus erythematosus (SLE), hospital readmission rate is associated with quality of care and prognosis. Our objective was to evaluate independent…
  • Abstract Number: 0721 • ACR Convergence 2020

    Validation of New Antirheumatic Drug Use as a Proxy for Increased JIA Disease Activity

    Avinash Gabbeta1, Evan Mulvihill2, Timothy Beukelman3, James Lewis4, Carlos Rose5, Brian Strom6 and Daniel Horton7, 1St. Christopher's Hospital for Children, Philadelphia, PA, 2Nemours A.I. duPont Hospital for Children, Wilmington, DE, 3University of Alabama at Birmingham, Birmingham, AL, 4University of Pennsylvania, Philadelphia, PA, 5Nemours A.I. duPont Hospital for Children, Wilmingon, DE, 6Rutgers University, Newark, NJ, 7Rutgers University, New Brunswick, NJ

    Background/Purpose: Administrative claims databases are valuable tools for studying treatment effects in large JIA populations but do not contain direct measures of disease activity, limiting…
  • Abstract Number: 1476 • ACR Convergence 2020

    Trends in Mortality and Cause-specific Mortality Among Patients with Psoriasis and Psoriatic Arthritis in Ontario, Canada

    Keith Colaco1, Jessica Widdifield2, Jin Luo3, Cheryl Rosen4, Raed Alhusayen5, J. Michael Paterson6, Willemina Campbell7, Karen Tu4, Sasha Bernatsky8, Dafna Gladman9 and Lihi Eder10, 1Institute of Medical Science, University of Toronto; Women's College Research Institute, Women's College Hospital; and Toronto Western Hospital, University Health Network, Toronto, ON, Canada, 2University of Toronto - Toronto, Toronto, ON, Canada, 3ICES, Toronto, Toronto, ON, Canada, 4University of Toronto, Toronto, ON, Canada, 5Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada, 6ICES, University of Toronto, Toronto, ON, Canada, 7University Health Network, University of Toronto, Toronto, ON, Canada, 8The Research Institute of the McGill University Health Centre, Montreal, ON, Canada, 9Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, 10Women’s College Research Institute, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Several studies have consistently demonstrated that psoriasis is associated with an increased risk of mortality compared to the general population. However, the excess risk…
  • Abstract Number: 0163 • ACR Convergence 2020

    Cost of Non-Persistence in the Treatment with Subcutaneous Tumor Necrosis Factor-Alpha Inhibitors of Inflammatory Arthritis: A Propensity Score Matching Approach

    Johan Dalén1, Karin Luttropp1, Tor Olofsson2, Christopher Black3 and Amy Puenpatom4, 1ICON plc, Stockholm, Sweden, Stockholm, Sweden, 2Department of Clinical Sciences, Lund, Rheumatology, Lund University, Sweden; Department of Rheumatology, Skåne University Hospital, Lund, Sweden, Lund, Sweden, 3Merck & Co., Inc., Kenilworth, NJ, USA, Rahway, NJ, 4Merck & Co., Inc., Kenilworth, NJ, USA, North Wales, PA

    Background/Purpose: Few studies have explored cost consequences of non-persistence in the treatment with Subcutaneous Tumor Necrosis Factor-Alpha Inhibitors (SC-TNFi) in Inflammatory Arthritis (IA; rheumatoid arthritis…
  • Abstract Number: 0815 • ACR Convergence 2020

    Initial Pharmaceutical Management in a National Cohort of Elderly-Onset Rheumatoid Arthritis Patients

    Deepan Dalal1, Tingting Zhang2, Hiren Varma2 and Theresa Shireman2, 1Brown University, East Providence, RI, 2Brown University, Providence, RI

    Background/Purpose: Methotrexate is the preferred initial drug for treatment of rheumatoid arthritis (RA) per American College of Rheumatology guidelines (2015). People with elderly-onset RA, classified as onset…
  • Abstract Number: 1609 • ACR Convergence 2020

    The Accuracy of Administrative Health Data for Identifying Patients with Rheumatoid Arthritis: A Validation Study Using Medical Records in Western Australia

    Khalid Almutairi1, Johannes Nossent1, David Preen1, Helen Keen1, Katrina Rogers2 and Charles Inderjeeth1, 1The University of Western Australia, Perth, Western Australia, Australia, 2Sir Charles Gairdner Hospital, Perth, Western Australia, Australia

    Background/Purpose: The use of large administrative health datasets is increasingly important in Rheumatology for disease trends and outcome research. We established the West Australian Rheumatic…
  • Abstract Number: 0179 • ACR Convergence 2020

    Identification of Multimorbidity Patterns in Rheumatoid Arthritis Through Machine Learning

    Bryant England1, Yangyuna Yang1, Punyasha Roul1, Christian Haas2, Lotfollah Najjar2, Harlan Sayles1, Fang Yu1, Brian Sauer3, Joshua Baker4, Kaleb Michaud1, Fenglong Xie5, Jeffrey R Curtis6 and Ted Mikuls1, 1University of Nebraska Medical Center, Omaha, NE, 2University of Nebraska Omaha, Omaha, NE, 3University of Utah, Omaha, NE, 4University of Pennsylvania, Philadelphia, PA, 5University of Alabama at Birmingham, Birmingham, AL, 6Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Chronic conditions often complicate the disease course of rheumatoid arthritis (RA) and predispose to poor long-term outcomes. The interrelationship of individual chronic conditions and…
  • Abstract Number: 0819 • ACR Convergence 2020

    The Adherence Patterns Among Patients Using Infliximab Bio-originator and Biosimilar

    Joseph Alanaeme1, Sujith Sarvesh1, Jeffrey R Curtis2 and Huifeng Yun2, 1University of Alabama at Birmingham, BIrmingham, AL, 2Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Infliximab (INF) biosimilar was approved for multiple indications in U.S. in 2016. Although clinical trials have demonstrated that switching from infliximab bio-originator to its…
  • « Previous Page
  • 1
  • …
  • 10
  • 11
  • 12
  • 13
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology